ClinicalTrials.gg
CompletedNCT06976372Updated Oct 8, 2025

A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

A Phase 1 interventional study of AMG 133 in Overweight and Obesity, sponsored by Amgen. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-08.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Aug 2024, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
21st of 28
120 · median 275
Started
2024
with 4 others
Phase 1
14 of 28
3 open now
Registered
7th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 21st largest by enrollment, is one of 5 that started in 2024, is one of 14 in phase 1, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

Keywords

  • Overweight
  • Obesity
  • Maridebart cafraglutide
  • AMG 133
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 120 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided before initiation of any study-specific activities/procedures.
  2. Male or female participants, between 18 and 65 years of age (inclusive) at the time of Screening.
  3. Except for obesity, no findings from medical history, physical examination, 12-lead (ECG), vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) as assessed by the Investigator (or designee). Participants with obstructive sleep apnea, controlled hypertension, and/or controlled dyslipidemia on stable therapies will be permitted. Participants with other mild, well-controlled comorbidities may be permitted with approval of the Investigator (or designee) in consultation with the Medical Monitor as appropriate.
  4. ≥ 27 kg/m\^2 at the time of Screening.
  5. Have a stable body weight (\< 5 kg self-reported change) within 3 months before Screening, as assessed by the Investigator (or designee) based on participant self-report. Have not modified diet or adopted any nutritional lifestyle modification for 3 months, as assessed by the Investigator (or designee) based on participant self-report.

Exclusion criteria

Exclusion Criteria

  1. History or evidence, at Screening or Check-in, of disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  2. History of or active diabetes (regardless of type with the exception of gestational diabetes), or ≥ 6.5% (≥ 48 mmol/mol), at Screening.
  3. History or evidence of endocrine disorder (such as Cushing's Syndrome) that can cause obesity.
  4. History of acute or chronic pancreatitis within 1 year prior to Check-in, or elevation in serum lipase/amylase (> 2x the ) at Screening, or fasting serum triglyceride level of > 500 mg/dL at Screening. One repeat of abnormal values will be allowed.
  5. except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ within the last 5 years.
  6. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  7. Uncontrolled thyroid disease, defined as thyroid-stimulating hormone (TSH) > 6.0 mIU/L or \< 0.4 mIU/L at Screening. Participants who receive treatment for hypothyroidism are permitted if their thyroid hormone replacement dose has been stable for 3 months prior to Screening and TSH criteria are met.
  8. History of or current signs of gastroparesis.
  9. Previous surgical procedure for obesity within 6 months prior to Check-in.
  10. History or current signs or symptoms of cardiovascular disease (aside from controlled hypertension and controlled dyslipidemia), including but not limited to myocardial infarction, congenital heart disease, valvular heart disease, coronary revascularization, or angina.
  11. History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the taken at Screening or Check-in.
  12. History of or allergy to AMG 133 or its ingredients, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  13. Estimated less than ≤ 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease equation at Screening or Check-in. One repeat of abnormal values will be allowed.
  14. or aspartate aminotransferase > 2x the upper limit of normal at Screening or Check-in. One repeat of abnormal values will be allowed.
  15. History of or current suicidal ideation (thoughts), suicide attempt(s), or major psychiatric illness (including depression) within 6 months prior to Screening.
  16. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before Check-in.
  17. Current use or prior use of any glucagon-like peptide 1 receptor (GLP-1R) agonist, GIPR glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist or antagonist within the past 3 months prior to Check-in.
  18. Current or prior use of all herbal medicines (e.g., St. John's wort), vitamins, and supplements consumed by the participant within the 30 days prior to enrollment, unless deemed acceptable by the Investigator (or designee) and in consultation with the Sponsor.
  19. Female participants of with a positive pregnancy test assessed at Screening or Check-in by a serum or urine pregnancy test.
  20. Female participants lactating/breastfeeding or who plan to breastfeed during the study through 16 weeks after the last dose of AMG 133.
  21. Unwilling to adhere to requirements through 16 weeks after the last dose of AMG 133.
  22. Participant has received a dose of an drug within the past 30 days or 5 half-lives, whichever is longer, prior to Check-in.
  23. Have previously completed or withdrawn from this study or any other study investigating AMG 133 or have previously received the investigational product.
  24. Unwilling to abide with study restrictions.
  25. Participants who, in the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    AMG 133 Dose A

    Participants will receive AMG 133 Dose A SC, followed by subsequent doses of Dose C and Dose D.

    Drug: AMG 133

  • Experimental
    AMG 133 Dose B

    Participants will receive AMG 133 Dose B SC, followed by subsequent doses of Dose C and Dose D.

    Drug: AMG 133

  • Experimental
    AMG 133 Dose C

    Participants will receive AMG 133 Dose C SC, followed by subsequent doses of Dose C and Dose D.

    Drug: AMG 133

Interventions

  • AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.

07

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax) of AMG 133

    Time frame: Up to Day 99

  2. Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133

    Time frame: Day 29

  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 133

    Time frame: Day 29

  4. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau) of AMG 133

    Time frame: Day 1 and Day 15

Secondary outcomes

  1. Number of Participants Who Experience Treatment-emergent Adverse Events

    Time frame: Up to Day 99

  2. Number of Participants Who Experience Serious Adverse Events

    Time frame: Up to Day 99

  3. Number of Participants Who Develop Anti-AMG 133 Antibodies

    Time frame: Up to Day 99

08

Study locations

3 sites
  • CenExel
    Anaheim, California 92801, United States
  • CenExel Collaborative Neuroscience Research, LLC Los Alamitos
    Los Alamitos, California 90720, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Dec 2024, 4 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 16, 2025
StartActual
Aug 20, 2024
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Last update
Oct 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06976372
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Aug 20, 2024
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Last update
Oct 8, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion